Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter Phase 2 study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented...

Related Keywords

Spain ,Israel ,United States ,American , ,American Society Of Clinical Oncology ,Bristol Myers Squibb ,Purple Biotech Ltd ,Purple Biotech ,Clinical Oncology ,Bristol Myers ,